Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) rose 11.5% during mid-day trading on Wednesday . The company traded as high as $10.37 and last traded at $10.40. Approximately 629,368 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 1,181,896 shares. The stock had previously closed at $9.33.
Analyst Upgrades and Downgrades
AVXL has been the subject of a number of recent research reports. D. Boral Capital reiterated a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th. HC Wainwright reiterated a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th.
View Our Latest Analysis on AVXL
Anavex Life Sciences Stock Up 1.4%
The business has a 50 day moving average price of $8.60 and a 200-day moving average price of $9.13. The firm has a market cap of $915.17 million, a price-to-earnings ratio of -19.49 and a beta of 0.72.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. During the same period last year, the business posted ($0.13) EPS. Research analysts anticipate that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Vermillion Wealth Management Inc. acquired a new position in shares of Anavex Life Sciences in the 4th quarter worth approximately $34,000. Tower Research Capital LLC TRC grew its position in shares of Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 1,708 shares in the last quarter. E Fund Management Co. Ltd. acquired a new position in shares of Anavex Life Sciences in the 1st quarter worth approximately $102,000. Prudential Financial Inc. acquired a new position in shares of Anavex Life Sciences in the 4th quarter worth approximately $109,000. Finally, 180 Wealth Advisors LLC acquired a new position in shares of Anavex Life Sciences in the 1st quarter worth approximately $121,000. Institutional investors own 31.55% of the company's stock.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
